JP6867652B2 - 癌療法のためのモノマレイミド官能化白金化合物 - Google Patents

癌療法のためのモノマレイミド官能化白金化合物 Download PDF

Info

Publication number
JP6867652B2
JP6867652B2 JP2018529981A JP2018529981A JP6867652B2 JP 6867652 B2 JP6867652 B2 JP 6867652B2 JP 2018529981 A JP2018529981 A JP 2018529981A JP 2018529981 A JP2018529981 A JP 2018529981A JP 6867652 B2 JP6867652 B2 JP 6867652B2
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
cancer
compound
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018529981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538292A5 (cg-RX-API-DMAC10.html
JP2018538292A (ja
Inventor
コヴォル，クリスティアン
ヘフェテル，ペトラ
ベルガー，ヴァルター
ケプラー，ベルンハルト・カー
マイヤー，ヨーゼフ
ピヒラー，ヴェレーナ
Original Assignee
メディツィニシェ ウニベルジテート ウィーン
メディツィニシェ ウニベルジテート ウィーン
ウニベルジテート ウィーン
ウニベルジテート ウィーン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディツィニシェ ウニベルジテート ウィーン, メディツィニシェ ウニベルジテート ウィーン, ウニベルジテート ウィーン, ウニベルジテート ウィーン filed Critical メディツィニシェ ウニベルジテート ウィーン
Publication of JP2018538292A publication Critical patent/JP2018538292A/ja
Publication of JP2018538292A5 publication Critical patent/JP2018538292A5/ja
Application granted granted Critical
Publication of JP6867652B2 publication Critical patent/JP6867652B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018529981A 2015-12-09 2016-12-09 癌療法のためのモノマレイミド官能化白金化合物 Expired - Fee Related JP6867652B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15198739 2015-12-09
EP15198739.3 2015-12-09
PCT/EP2016/080453 WO2017097986A1 (en) 2015-12-09 2016-12-09 Monomaleimide-functionalized platinum compounds for cancer therapy

Publications (3)

Publication Number Publication Date
JP2018538292A JP2018538292A (ja) 2018-12-27
JP2018538292A5 JP2018538292A5 (cg-RX-API-DMAC10.html) 2020-01-23
JP6867652B2 true JP6867652B2 (ja) 2021-05-12

Family

ID=54849106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018529981A Expired - Fee Related JP6867652B2 (ja) 2015-12-09 2016-12-09 癌療法のためのモノマレイミド官能化白金化合物

Country Status (21)

Country Link
US (2) US10723748B2 (cg-RX-API-DMAC10.html)
EP (1) EP3386997B1 (cg-RX-API-DMAC10.html)
JP (1) JP6867652B2 (cg-RX-API-DMAC10.html)
CN (1) CN108368143B (cg-RX-API-DMAC10.html)
AU (1) AU2016367306B2 (cg-RX-API-DMAC10.html)
CA (1) CA3004630A1 (cg-RX-API-DMAC10.html)
CY (1) CY1124529T1 (cg-RX-API-DMAC10.html)
DK (1) DK3386997T3 (cg-RX-API-DMAC10.html)
ES (1) ES2898704T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20211466T1 (cg-RX-API-DMAC10.html)
HU (1) HUE056897T2 (cg-RX-API-DMAC10.html)
IL (1) IL259864B (cg-RX-API-DMAC10.html)
LT (1) LT3386997T (cg-RX-API-DMAC10.html)
MX (1) MX377528B (cg-RX-API-DMAC10.html)
PL (1) PL3386997T3 (cg-RX-API-DMAC10.html)
PT (1) PT3386997T (cg-RX-API-DMAC10.html)
RS (1) RS62412B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201804885TA (cg-RX-API-DMAC10.html)
SI (1) SI3386997T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202100709T1 (cg-RX-API-DMAC10.html)
WO (1) WO2017097986A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016030310A2 (pt) * 2014-06-23 2017-08-22 Placon Therapeutics Inc Compostos de platina, composições e seus usos
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN109171001A (zh) * 2018-09-14 2019-01-11 上海烟草集团有限责任公司 草酸钠在降低卷烟烟气中TSNAs释放量中的应用
WO2021138215A1 (en) * 2019-12-31 2021-07-08 Kinnate Biopharma Inc. Treatment of cancer with cdk12/13 inhibitors
CN114163479B (zh) * 2020-09-11 2025-05-16 上海海聚生物科技有限公司 一类治疗癌症用的铂类化合物及其制备方法
US20230339997A1 (en) * 2020-09-11 2023-10-26 Shanghai Haiju Biological Technology Co., Ltd. Class of platinum compounds for treating cancer, and method for preparation thereof
CN114539320B (zh) * 2020-11-25 2026-01-27 北京大学 辐射激活的四价铂配合物及其用途
WO2026132589A1 (en) 2024-12-19 2026-06-25 Universität Wien Egfr inhibitor-functionalized albumin-binding platinum compounds for cancer therapy

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH605550A5 (cg-RX-API-DMAC10.html) 1972-06-08 1978-09-29 Research Corp
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS607934A (ja) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
CS269719B1 (en) 1986-12-29 1990-05-14 Kiss Frantisek Platinum cytostatic
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
ATE248583T1 (de) 1997-09-29 2003-09-15 Nektar Therapeutics In dosierinhalatoren verwendbare, stabilisierte zubereitungen
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
DE10314780A1 (de) 2003-03-19 2004-09-30 Ktb Tumorforschungsgesellschaft Mbh Proteinbindende Derivate von Platinkomplexen mit Cyclobutan-1,1-dicarboxylatliganden
JP2006521300A (ja) 2003-03-31 2006-09-21 プリヴァ−ラケマ，エー．エス． 活性物質として白金錯体を含有する医薬組成物およびその製造方法
CZ296169B6 (cs) 2004-09-08 2006-01-11 Pliva - Lachema A. S. Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
CZ2004964A3 (cs) 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
US20060205810A1 (en) 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
CZ300424B6 (cs) 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
CZ300120B6 (cs) 2006-06-20 2009-02-11 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
CZ300590B6 (cs) 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
BR112014013526A8 (pt) 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
CN104302408B (zh) * 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
WO2015052516A1 (en) * 2013-10-08 2015-04-16 Atlas Genetics Limited Labelling compounds and their use in assays
EP3089745A4 (en) 2013-12-31 2017-05-17 Placon Therapeutics, Inc. Compounds, compositions, and methods for the treatment of cancers
BR112016030310A2 (pt) * 2014-06-23 2017-08-22 Placon Therapeutics Inc Compostos de platina, composições e seus usos
US10342801B2 (en) 2015-06-23 2019-07-09 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
US20180186823A1 (en) 2015-06-23 2018-07-05 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
WO2017004123A1 (en) 2015-06-29 2017-01-05 Case Western Reserve University Anticancer drug-containing plant virus particles
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
JP2019524706A (ja) 2016-07-08 2019-09-05 ジェネンテック， インコーポレイテッド Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
WO2018026742A1 (en) 2016-08-01 2018-02-08 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
CN108164512B (zh) 2017-12-27 2021-05-25 沈阳药科大学 一类具有生物粘附作用的马来酰亚胺型前药及其在口服药物传递中的应用
CN108187063B (zh) 2018-01-09 2020-09-08 沈阳药科大学 白蛋白结合型抗肿瘤药-马来酰亚胺分子前药

Also Published As

Publication number Publication date
SI3386997T1 (sl) 2021-11-30
LT3386997T (lt) 2021-12-10
PL3386997T3 (pl) 2021-12-13
HUE056897T2 (hu) 2022-03-28
AU2016367306A1 (en) 2018-06-14
MX377528B (es) 2025-03-10
HRP20211466T1 (hr) 2021-12-24
AU2016367306B2 (en) 2021-04-22
US20180354979A1 (en) 2018-12-13
SMT202100709T1 (it) 2022-01-10
CN108368143A (zh) 2018-08-03
IL259864A (en) 2018-07-31
US11572379B2 (en) 2023-02-07
DK3386997T3 (da) 2021-09-20
EP3386997A1 (en) 2018-10-17
IL259864B (en) 2022-07-01
EP3386997B1 (en) 2021-06-30
US20210002313A1 (en) 2021-01-07
MX2018006953A (es) 2019-05-16
RS62412B1 (sr) 2021-10-29
CN108368143B (zh) 2022-02-01
US10723748B2 (en) 2020-07-28
SG11201804885TA (en) 2018-07-30
CA3004630A1 (en) 2017-06-15
JP2018538292A (ja) 2018-12-27
ES2898704T3 (es) 2022-03-08
PT3386997T (pt) 2021-11-04
CY1124529T1 (el) 2022-07-22
WO2017097986A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
CN108368143B (zh) 用于癌症疗法的单马来酰亚胺官能化的铂化合物
KR101915452B1 (ko) 백금 화합물, 조성물 및 이의 용도
JP7121660B2 (ja) 癌を処置するためのｅｚｈ２阻害剤の使用
TWI642667B (zh) 吡啶並嘧啶類衍生物、其製備方法及其在醫藥上的應用
CN105940005A (zh) 二氮杂环庚烷衍生物及其用途
JP2018522867A (ja) 縮合二環式ピリミジン誘導体およびこれらの使用
CN113474014A (zh) 放射性免疫缀合物与dna损伤和修复抑制剂组合疗法
TR201807023T4 (tr) Abl1, abl2 ve bcr- abl1 aktivitesinin inhibe edilmesi için benzamid türevleri.
JP5636091B2 (ja) 癌治療に用いるためのコンブレタスタチン類似体
CN114728934B (zh) 杂环衍生物、药物组合物和它们治疗或改善癌症的用途
JP2023095928A (ja) 癌を処置するためのｅｚｈ２阻害剤の使用
JP2023545588A (ja) ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用
JP2021514955A (ja) プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法
CN106572991A (zh) 用于克服铂耐受性的德克萨卟啉‑pt(iv)缀合物及组合物
CN108602807B (zh) 杂环磺酰胺衍生物及含有其的药物
KR20220062363A (ko) 암 표적성 약물 전달체로서의 인지질 에테르 접합체
CN117545479A (zh) Pi3k抑制剂、纳米制剂及其用途
JP7673982B2 (ja) プロスタグランジンｅ２（ｐｇｅ２）ｅｐ４受容体アンタゴニスト
JP2019514969A (ja) 分子イメージング及びがんの免疫療法のためのδオピオイド受容体標的化薬
CN116056698A (zh) 具有血脑屏障穿透能力的取代的1-(3,3-二氟哌啶-4-基)-咪唑并[4,5-c]喹啉-2-酮化合物
WO2025132831A1 (en) N-heteroaryl derivatives and uses thereof for treating cancer
EA047198B1 (ru) Конъюгаты фосфолипид-флаваглин и способы их применения для нацеленной противораковой терапии
HK40014041B (en) Myeloperoxidase imaging agents
HK40014041A (en) Myeloperoxidase imaging agents
HK1236416A1 (zh) 用於克服铂耐受性的德克萨卟啉-pt(iv)缀合物及组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210319

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210401

R150 Certificate of patent or registration of utility model

Ref document number: 6867652

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees